𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Beneficial hepatic effect of troglitazone in a patient with antimitochondrial antibody-negative primary biliary cirrhosis

✍ Scribed by Takashi Okai; Hisatsugu Mouri; Yasushi Yamaguchi; Yasuni Nakanuma; Norio Sawabu

Book ID
119392047
Publisher
Nature Publishing Group
Year
2002
Tongue
English
Weight
40 KB
Volume
97
Category
Article
ISSN
0002-9270

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Increased prevalence of antimitochondria
Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis
✍ Konstantinos N. Lazaridis; Brian D. Juran; Gwen M. Boe; Joshua P. Slusser; Mariz πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 187 KB πŸ‘ 1 views

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disorder that can progress to cirrhosis, shortening life expectancy. PBC patients are often asymptomatic, present with biochemical cholestasis, and test positive (>90%) for antimitochondrial antibodies (AMAs) in serum. Although AMA posit

Abnormal expression of PDC-E2 on the api
Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis
✍ Koichi Tsuneyama; Judy van de Water; David van Thiel; Ross Coppel; Boris Ruebner πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 945 KB

The presence of antimitochondrial antibodies (AMA) is a major criterion for the diagnosis of primary biliary cirrhosis (PBC). Although it is not clear that AMA are involved in the pathogenesis of the disease, the study of these autoantibodies has enabled much information to be accumulated about the